Earnings summaries and quarterly performance for Zura Bio.
Executive leadership at Zura Bio.
Board of directors at Zura Bio.
AM
Amit Munshi
Detailed
Chairman of the Board
AP
Arnout Ploos van Amstel
Detailed
Director
DB
Dan Becker
Detailed
Director
JJ
Jennifer Jarrett
Detailed
Director
NG
Neil Graham
Detailed
Director
RL
Robert Lisicki
Detailed
Director
SK
Sandeep Kulkarni
Detailed
Director
SS
Someit Sidhu
Detailed
Director
SS
Steve Schoch
Detailed
Director
Research analysts covering Zura Bio.
Recent press releases and 8-K filings for ZURA.
Zura Bio Announces Clinical Trial Timelines and Cash Guidance
ZURA
Guidance Update
New Projects/Investments
- Zura Bio provided business updates and its outlook for 2026, including revised timelines for key clinical trial readouts and cash guidance.
- The company now expects topline data from its expanded Phase 2 TibuSHIELD trial in hidradenitis suppurativa (HS) in the fourth quarter of 2026.
- Topline data for the Phase 2 TibuSURE study in systemic sclerosis (SSc) is anticipated in the first half of 2027.
- Zura Bio's cash and cash equivalents, which were $139 million as of September 30, 2025, are expected to fund planned operations through 2027, extending beyond the anticipated data readouts for both HS and SSc.
7 days ago
Zura Bio Enters into New Agreements with Athanor Capital, Terminates Previous Pacts
ZURA
Legal Proceedings
New Projects/Investments
- Zura Bio Limited entered into new agreements with Athanor Capital on December 29, 2025, which superseded and terminated all previous agreements with Stone Peach Properties LLC and BAFFX17, extinguishing their prior rights and claims.
- Under the new Athanor Agreement, Zura Bio will issue 8,657,402 Class A ordinary shares to Athanor Capital.
- Additionally, Zura Bio committed to pay Athanor Capital an initial fee of $7,325,000 within thirty days and a one-time milestone payment of $25,000,000 upon the earliest occurrence of specific events, along with 2% of Net Sales for the Product under certain conditions.
Jan 2, 2026, 9:19 PM
Zura Bio Reports Q3 2025 Financial Results and Clinical Trial Progress
ZURA
Earnings
Guidance Update
New Projects/Investments
- Zura Bio reported $139.0 million in cash and cash equivalents as of September 30, 2025, which is expected to fund planned operations through 2027.
- The company recorded a net loss of $20.0 million, or $0.21 per share, for the third quarter of 2025.
- Research and development expenses for Q3 2025 were $11.9 million, reflecting the continued advancement of the tibulizumab Phase 2 clinical trials.
- Zura Bio continued to advance its two Phase 2 clinical trials for tibulizumab (TibuSHIELD for hidradenitis suppurativa and TibuSURE for systemic sclerosis), with topline data for both studies expected in the second half of 2026.
Nov 13, 2025, 11:30 AM
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more